WORCESTER, Mass. and TORONTO, Sept. 30, 2014 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced that it has engaged Dr. Lakshmi P. Kotra, B. Pharm.(Hons), Ph.D., as a consultant to the Company to provide expertise and assistance in the management of the Company's previously announced buccal insulin enhancement project. In this role, Dr. Kotra will work closely with the Company's Senior Scientific Advisor, Dr. James H. Anderson, Jr., MD, and Company management working to increase the insulin bioavailability of Generex Oral-lyn, the Company's proprietary buccal insulin spray product, thereby reducing the number of puffs required to achieve effective prandial metabolic control for patients with diabetes.
Dr. Kotra is the Director at the Center for Molecular Design and Preformulations (CMDP) at University Health Network (UHN) in Toronto, Canada, a Scientist and Principal Investigator at UHN, and an Associate Professor of Medicinal Chemistry at the Leslie Dan Faculty of Pharmacy, University of Toronto (http://www.uhnresearch.ca/kotralab). Dr. Kotra received a Ph.D. in pharmacy from the University of Georgia and postdoctoral training at Wayne State University in Michigan. Dr. Kotra has authored/co-authored over 100 publications including peer-reviewed scientific manuscripts, expert review articles, and book chapters, 20 patents/patent applications, and delivered more than 95 invited talks around the world. Dr. Kotra has broad expertise in preclinical drug discovery and development, and has conducted research in a broad spectrum of therapeutic areas.
Dr. Kotra is the recipient of several awards including the Premier's Research Excellence Award from the Province of Ontario, the Rx&D Health Research Foundation Research Career award, and the GlaxoSmithKline/Canadian Society for Pharmaceutical Sciences Young Investigator Award.
"I have a frontline understanding of the need for better delivery of insulin, and I see this relationship as a great opportunity to engage in such transformative activity. It is with great anticipation that I embark upon this exciting project with Generex," commented Dr. Kotra. "Having achieved a comprehensive understanding of Generex's activities to date, and participated in several discussions with the Generex team, I strongly believe in the potential for Generex Oral-lyn in the North American market. I look forward to working with Dr. Anderson and his team to strategize the R&D in this direction and help advance the Company's clinical and regulatory efforts."
Generex Oral-lyn is designed to be a safe, simple, fast, flexible, and effective alternative to prandial insulin injections.
About Generex Biotechnology Corporation
Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist device. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T-helper stimulation technologies in immunotherapy. One focuses on modification of peptides with Ii-Key to increase potency, while a second relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T-helper cells and prevents the further growth of cancer cells. For more information, visit the Generex website at www.generex.comor the Antigen Express website at www.antigenexpress.com.
Cautionary Note Regarding Forward-Looking Statements
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials or ultimate regulatory approval cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials or when it will obtain ultimate regulatory approval by a particular regulatory agency. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
SOURCE Generex Biotechnology Corporation